Pular para o conteúdo
Merck
  • Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox.

Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox.

Scientific reports (2017-02-28)
Bharatwaj Sowrirajan, Yoshiro Saito, Deepak Poudyal, Qian Chen, Hongyan Sui, Suk See DeRavin, Hiromi Imamichi, Toyotaka Sato, Douglas B Kuhns, Noriko Noguchi, Harry L Malech, H Clifford Lane, Tomozumi Imamichi
RESUMO

Interleukin (IL)-27, a member of the IL-12 cytokine family, plays an important and diverse role in the function of the immune system. We have previously demonstrated that IL-27 is an anti-viral cytokine which inhibits HIV-1, HIV-2, Influenza virus and herpes simplex virus infection, and enhances the potential of reactive oxygen species (ROS) generating activity during differentiation of monocytes to macrophages. In this study, we further investigated the mechanism of the enhanced potential for ROS generation by IL-27. Real time PCR, western blot and knock down assays demonstrate that IL-27 is able to enhance the potential of superoxide production not only during differentiation but also in terminally differentiated-macrophages and immature dendritic cells (iDC) in association with the induction of p47phox, a cytosolic component of the ROS producing enzyme, NADPH oxidase, and the increase in amounts of phosphorylated p47phox upon stimulation. We also demonstrate that IL-27 is able to induce extracellular superoxide dismutase during differentiation of monocytes but not in terminal differentiated macrophages. Since ROS plays an important role in a variety of inflammation, our data demonstrate that IL-27 is a potent regulator of ROS induction and may be a novel therapeutic target.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Anti-α-Actinin Antibody, clone AT6/172, clone AT6/172, Upstate®, from mouse
Sigma-Aldrich
MISSION® esiRNA, targeting human NCF1